Fidelity SPDR Advertisement
Home > Boards > US Listed > Biotechs >

Idera Pharmaceuticals, Inc. (IDRA)

IDRA RSS Feed
Add IDRA Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator TOB, Seel
Search This Board:
Last Post: 11/22/2014 10:05:35 PM - Followers: 111 - Board type: Free - Posts Today: 0



The Company has created DNA-based compounds that in preclinical studies act as antagonists of TLR7 and TLR9, such as IMO-3100, or as antagonists of TLRs 7, 8, and 9, such as IMO-8400. The Company is developing IMO-3100, an antagonist of TLR7 and TLR9, for the treatment of psoriasis. It has selected IMO-8400, an antagonist of TLRs 7, 8, and 9, for development in the treatment of autoimmune diseases, with lupus as the initial disease indication. IMO-2055, a TLR9 agonist, is its lead drug candidate for the treatment of cancer. Clinical trials of IMO-2055 completed by the Company or by Merck KGaA include four Phase I clinical trials, of which two were in healthy subjects and two were in refractory cancer patients, and one Phase II clinical trial. The Phase II clinical trial was a monotherapy trial of IMO-2055 in patients with metastatic or recurrent clear cell renal cancer.


In preclinical animal models, the Company TLR7, 8, and 9 agonists have shown adjuvant activity when combined with various types of antigens. It has designed and created a new class of molecules to inhibit gene expression. These gene silencing oligonucleotides, which it refer to as GSOs, are nucleic acid-based and represent a novel approach to selectively, silence gene expression. It is actively engaged in preclinical research with its GSOs that is designed to explore their potential as research reagents and therapeutic agents. In addition to the Company’s clinical programs in autoimmune and inflammatory diseases and in cancer, it has identified TLR drug candidates for applications in the treatment of infectious diseases, respiratory diseases and hematological malignancies, and TLR3 agonists for use as vaccine adjuvants.


IMO-2125, a synthetic DNA-based TLR9 agonist, is its lead candidate for the treatment of chronic hepatitis C virus (HCV), infection. The Company conducted two Phase I clinical trials of IMO-2125 in patients with chronic HCV infection, one in patients with HCV who had not responded to prior treatment and one in combination with ribavirin, an antiviral medication approved for use in combination with interferon-alpha in the treatment of HCV infection, in treatment-naive patients with genotype 1 chronic HCV infection. In addition to the use of TLR9 agonists in oncology applications, it selected IMO-4200 as a lead TLR7 and TLR8 agonist candidate for the treatment of hematological cancers. Its TLR9 agonists are designed to induce immune responses that could be useful in restoring immune system balance. IMO-2134 is its lead TLR9 agonist for asthma and allergies. In addition to use of TLR7, 8, and 9 agonists as vaccine adjuvants, it also has created TLR3 agonists for potential use as vaccine adjuvants.


The Company competes with Dynavax Technologies Corporation, GlaxoSmithKline plc., Pfizer, Inc., VentiRx Pharmaceuticals., Novartis, Dynavax Technologies Corporation, VaxInnate, Inc., Intercell AG, Cytos Biotechnology AG and Celldex Therapeutics, Inc.

http://www.iderapharma.com/

 


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
IDRA
Current Price
Volume:
Bid Ask Day's Range
Wiki
Option Chain for IDRA
IDRA News: Quarterly Report (10-q) 11/07/2014 06:08:17 AM
IDRA News: Statement of Changes in Beneficial Ownership (4) 10/03/2014 05:56:00 PM
IDRA News: Confidential Treatment Order (ct Order) 09/17/2014 01:43:23 PM
IDRA News: Statement of Changes in Beneficial Ownership (4) 09/04/2014 04:23:04 PM
IDRA News: Statement of Changes in Beneficial Ownership (4) 08/18/2014 07:27:03 PM
PostSubject
#1337  Sticky Note Idera Pharmaceuticals and Collaborators Publish Promising reclinical Data TOB 08/06/14 11:05:37 AM
#718  Sticky Note Hi Seel. Let me assure you that despite ajsmith 03/09/14 01:35:35 AM
#1414   It's just my opinion and/or one big ball etradeedge 11/22/14 10:05:35 PM
#1413   Positive chart indicators continue building. Trading nicely in Citrati 11/11/14 07:14:29 PM
#1412   Lot of positive in the charts and a Citrati 11/10/14 03:58:37 PM
#1411   I hope these little "pops" of 6% aren't tprosuper 11/07/14 04:27:17 PM
#1410   finally...(sigh) Seel 11/06/14 12:12:33 PM
#1409   Nice pop today....NEWS Citrati 11/06/14 12:09:58 PM
#1408   Good to hear Seel. Glad you are still Citrati 10/23/14 12:37:25 PM
#1407   I kept a small core going here Citrati. Seel 10/23/14 12:33:11 PM
#1406   Buying into several small cap biotechs like IDRA surf1944 10/23/14 11:47:01 AM
#1405   Not many followers on this board. Try YMB. stocking4ms 10/23/14 07:02:43 AM
#1404   Has everyone abandoned this? Chugga, chugga. Citrati 10/23/14 01:04:34 AM
#1403   $IDRA Cowen Reiterates Outperform On Idera Following Initiation maytepper 10/14/14 03:12:26 PM
#1402   What I am most interested in is if Citrati 10/14/14 01:39:24 PM
#1401   +>>>IDRA - did i draw my fib lines Chrion Capital 10/14/14 01:03:55 PM
#1400   +>>>IDRA - Watching closely here at the two Chrion Capital 10/14/14 12:51:33 PM
#1399   Yes indeed. Very tradable action. Citrati 10/14/14 12:47:42 PM
#1398   If you have been paying attention last few Randolph Duke 10/14/14 12:30:46 PM
#1397   IMO, too early to call. General markets are Citrati 10/14/14 09:10:37 AM
#1396   Think the bottom is in yet? Bought Black sunshine 10/11/14 10:06:07 PM
#1395   Nice little pop from "fed minutes" and IBB Citrati 10/08/14 02:59:00 PM
#1394   Here are 20 million shares. Hard to figure Citrati 10/08/14 12:49:23 AM
#1393   This is about as ugly as it gets. etradeedge 10/07/14 10:38:35 PM
#1392   Bounce or plunge- pretty clear indeed Randolph Duke 10/07/14 09:18:03 PM
#1391   This doesn't need any explanation. Pretty crystal clear. Citrati 10/07/14 04:06:22 PM
#1390   Trying to hold 2.10 with 2.00 as last Citrati 10/06/14 12:22:27 PM
#1389   Not an open market buy, but bullish nonetheless imo. Canoepaddler 10/04/14 08:32:28 AM
#1388   Here is the link for anyone interested. Citrati 10/03/14 09:07:35 PM
#1387   Julian Baker added almost 27k shares 10/1 on Canoepaddler 10/03/14 07:05:17 PM
#1386   At least it held $2. I did risk Randolph Duke 10/03/14 11:11:26 AM
#1385   Buying opp... not burying opp... Freud would have macnqueso 10/03/14 08:30:44 AM
#1384   Lol... meant buying opp... not burying opp... but macnqueso 10/03/14 08:30:00 AM
#1383   Anything at 2 or below is a great macnqueso 10/03/14 08:19:09 AM
#1382   This will be interesting because if one goes Citrati 10/03/14 12:02:00 AM
#1381   nibbled at $2 today... wouldn't mind nibbling all macnqueso 10/02/14 08:53:55 PM
#1380   WAIT TILL 0.50 :) FROM THERE WE WILL taldhaliwal 10/02/14 05:34:47 PM
#1379   Things may continue to be quiet here for Seel 10/02/14 04:55:00 PM
#1378   I THINK THAT TOO I'M BUYING AT 1.51 taldhaliwal 10/02/14 12:26:23 PM
#1377   I REALLY LIKE THIS COMPANY... WHATS THE BOTTOM TOB 10/02/14 12:24:34 PM
#1376   I REALLY LIKE THIS COMPANY... WHATS THE BOTTOM taldhaliwal 10/02/14 12:15:45 PM
#1375   Not looking too good in any time frame. Citrati 10/01/14 08:40:42 PM
#1374   Let's hope, the previous support obviously didn't hold TOB 10/01/14 08:07:13 PM
#1373   Idra must have a lot of bottoms! Black sunshine 10/01/14 08:04:19 PM
#1372   Multi-bottom support being tested. TOB 09/25/14 10:08:12 PM
#1371   Jeez I hope so. $2.38 seems to Black sunshine 09/22/14 06:59:00 PM
#1370   Way oversold at this point- wouldn't ya say? Randolph Duke 09/22/14 12:15:37 PM
#1369   Confidential treatment Court order? Interesting monkeyfrog 09/17/14 01:55:46 PM
#1368   IDRA - in the right space at the Seel 09/12/14 01:44:20 PM
#1367   Big seller out. Might have been a pre Randolph Duke 09/05/14 10:46:03 AM
#1366   Do you have level 2? Are they mostly Citrati 09/03/14 03:26:03 PM
#1365   Someone is dumping and someone is sucking them Randolph Duke 09/03/14 01:36:25 PM
PostSubject